Colgate-Palmolive (CL) Aktienübersicht
Die Colgate-Palmolive Company und ihre Tochtergesellschaften produzieren und verkaufen Konsumgüter in den Vereinigten Staaten und weltweit. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 5/6 |
Belohnungen
Risikoanalyse
CL Community Fair Values
Create NarrativeSee what 142 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Colgate-Palmolive Company Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$88.13 |
| 52-Wochen-Hoch | US$99.33 |
| 52-Wochen-Tief | US$74.55 |
| Beta | 0.30 |
| 1 Monat Veränderung | 5.56% |
| 3 Monate Veränderung | -8.83% |
| 1 Jahr Veränderung | -3.40% |
| 3 Jahre Veränderung | 10.26% |
| 5 Jahre Veränderung | 4.63% |
| Veränderung seit IPO | 9,432.94% |
Aktuelle Nachrichten und Updates
Seeking Alpha • May 10
Colgate-Palmolive: Too Expensive For A Defensive Firm
Summary Colgate-Palmolive delivered 8% sales growth in Q1 2026, but EPS declined 6%, warranting a conservative hold rating. I see organic growth of just 2.9%, with North America sales falling due to increased toothpaste competition and margin compression. FX tailwinds drove significant growth in Latin America, EMEA, and APAC, raising concerns about sustainability if currency trends reverse. Persistent low U.S. consumer confidence and elevated input costs, including a $300M Middle East impact, create near-term headwinds for CL. Read the full article on Seeking Alpha
Narrativ-Update • Apr 09
CL: 2030 Plan Execution And Margins Will Shape 2026 Setup
Analysts have trimmed the Colgate-Palmolive fair value estimate by about $0.58 to $96.68, reflecting slightly softer revenue growth assumptions, a modestly lower future P/E, and mixed recent research that includes both reduced price targets and an upgrade tied to confidence in the 2030 plan and ongoing margin resilience. Analyst Commentary Recent Street research on Colgate-Palmolive shows a mix of optimism around the long-term plan and caution around nearer term cost and valuation risks.Recent updates
Seeking Alpha • May 10
Colgate-Palmolive: Too Expensive For A Defensive Firm
Summary Colgate-Palmolive delivered 8% sales growth in Q1 2026, but EPS declined 6%, warranting a conservative hold rating. I see organic growth of just 2.9%, with North America sales falling due to increased toothpaste competition and margin compression. FX tailwinds drove significant growth in Latin America, EMEA, and APAC, raising concerns about sustainability if currency trends reverse. Persistent low U.S. consumer confidence and elevated input costs, including a $300M Middle East impact, create near-term headwinds for CL. Read the full article on Seeking AlphaNarrativ-Update • Apr 09
CL: 2030 Plan Execution And Margins Will Shape 2026 Setup
Analysts have trimmed the Colgate-Palmolive fair value estimate by about $0.58 to $96.68, reflecting slightly softer revenue growth assumptions, a modestly lower future P/E, and mixed recent research that includes both reduced price targets and an upgrade tied to confidence in the 2030 plan and ongoing margin resilience. Analyst Commentary Recent Street research on Colgate-Palmolive shows a mix of optimism around the long-term plan and caution around nearer term cost and valuation risks.Narrativ-Update • Mar 25
CL: 2030 Plan And Emerging Markets Execution Will Shape 2026 Setup
Colgate-Palmolive's fair value estimate edges up to $97.26 from $97.21 as analysts lift price targets toward the $100 to $105 range, citing stronger confidence in the 2030 plan, product innovation, and emerging markets execution. Analyst Commentary Recent Street research on Colgate-Palmolive clusters around higher price targets and upgraded ratings, with the fair value conversation increasingly framed around the 2030 plan, execution in emerging markets, and portfolio moves such as the exit from private label pet food.Narrativ-Update • Mar 10
CL: 2030 Plan And Emerging Markets Support Measured 2026 Execution Setup
Analysts have nudged their price expectations for Colgate-Palmolive higher, with the updated fair value estimate moving from about $96.68 to roughly $97.21. They cite growing confidence in the company’s 2030 plan, product innovation efforts and emerging markets exposure, as reflected in a series of recent price target increases across major firms.Narrativ-Update • Feb 24
CL: 2030 Plan And Emerging Markets Will Drive Balanced 2026 Setup
Analysts have raised their implied price target for Colgate-Palmolive by about $8 to reflect higher conviction in the company’s 2030 plan, product innovation pipeline and emerging market exposure, as well as refreshed views on sector valuations. Analyst Commentary Recent research has centered on how Colgate-Palmolive’s 2030 plan, product pipeline and emerging market footprint feed into both growth potential and current valuation.Analyseartikel • Feb 06
There May Be Some Bright Spots In Colgate-Palmolive's (NYSE:CL) Earnings
Colgate-Palmolive Company's ( NYSE:CL ) recent soft profit numbers didn't appear to worry shareholders, as the stock...Narrativ-Update • Jan 28
CL: Emerging Markets And 2026 Setup Will Shape Balanced Risk Reward
Analysts have nudged their price targets for Colgate-Palmolive higher, reflected in a modest fair value move from about $87.47 to $88.89. They are factoring in slightly stronger revenue growth assumptions, a marginally higher future P/E and recent rating and target changes across firms such as Barclays, JPMorgan, UBS, Wells Fargo, Piper Sandler and TD Cowen.Narrativ-Update • Jan 10
CL: Emerging Markets And 2026 Setup Support Balanced Outlook After Recent Softness
Our updated analyst price target for Colgate-Palmolive edges up to about US$87.47 from roughly US$87.21, as analysts balance slightly softer modeled revenue growth with modestly higher profit margin and future P/E assumptions. This view is supported by recent research that pairs cautious consumer staples outlooks with a more positive stance on the company’s emerging markets exposure and potential 2026 acceleration.Narrativ-Update • Dec 15
CL: Emerging Market Strength Will Support Gradual Recovery As Q3 Softness Fades
Analysts have trimmed their price target on Colgate-Palmolive to $87 from the low-to-mid $90s, reflecting near term softness in Q3 results and muted personal care growth, even as they expect organic sales momentum to gradually improve. Analyst Commentary Analysts remain divided on Colgate-Palmolive, with recent target cuts reflecting near term execution risk, while longer term growth and margin recovery expectations stay largely intact.Narrativ-Update • Nov 30
CL: Gradual Recovery Expected As Temporary Headwinds Ease In Personal Care Markets
Narrative Update on Colgate-Palmolive Colgate-Palmolive's analyst price target has been modestly reduced by $0.05 to $87.21. Analysts cite near-term growth challenges and muted sector outlooks following a soft Q3, but expect gradual improvement as temporary pressures ease.Narrativ-Update • Nov 16
CL: Organic Sales Momentum Will Rebound As Near-Term Headwinds Ease
Colgate-Palmolive's analyst consensus price target was revised downward from approximately $88.84 to $87.26. Analysts cite a soft third quarter, moderated growth expectations, and ongoing category headwinds as key factors behind the adjustment.Narrativ-Update • Nov 02
CL: Future Cost Optimization Will Drive Competitive Advantage Amid Category Headwinds
Colgate-Palmolive’s fair value estimate has been reduced from $90.74 to $88.84 per share. Analysts cite persistent category headwinds and a moderated sales outlook as factors behind lower price targets across the sector.Narrativ-Update • Oct 18
Emerging Markets And Digital Transformation Will Unlock Global Value
Colgate-Palmolive's analyst fair value price target has decreased from $93.11 to $90.74. Analysts cite lowered sales guidance, persistent category headwinds, and muted growth outlooks as key factors behind their revised estimates.Narrativ-Update • Oct 03
Emerging Markets And Digital Transformation Will Unlock Global Value
Colgate-Palmolive's analyst price target has been revised downward by approximately $2 to $93. Analysts cite ongoing category headwinds and decelerating growth in the personal care sector as reasons for this adjustment.Analyseartikel • Sep 30
There's Reason For Concern Over Colgate-Palmolive Company's (NYSE:CL) Price
Colgate-Palmolive Company's ( NYSE:CL ) price-to-earnings (or "P/E") ratio of 22.3x might make it look like a sell...Analyseartikel • Aug 04
Colgate-Palmolive Company (NYSE:CL) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Shareholders might have noticed that Colgate-Palmolive Company ( NYSE:CL ) filed its quarterly result this time last...Analyseartikel • Jun 27
Colgate-Palmolive (NYSE:CL) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analyseartikel • Jun 12
Do Colgate-Palmolive's (NYSE:CL) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Apr 22
A Historic Brand, A Fresh Approach: Inside Colgate-Palmolive's Machine
Summary Colgate-Palmolive achieved over $20 billion in revenue in 2024, driven by strong brand identity, operational discipline, and a diversified product portfolio across Oral Care, Personal Care, Home Care, and Pet Nutrition. The company maintained profitability despite inflation, with a 14.4% margin, and continued to invest in marketing and R&D, enhancing brand differentiation and price stability. Financially robust, Colgate-Palmolive showed significant revenue and margin growth, generating record free cash flow, and is well-positioned for 2025 with a "Buy" rating and a target share price of $100.08. Key risks include currency fluctuations, raw material costs, and competition, but strong daily demand for products and innovation in high-growth segments like Pet Nutrition support long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Mar 20
Colgate-Palmolive: A Defensive Stock With Growth Potential
Summary Colgate-Palmolive is one of the leaders in the global toothpaste market. On January 31, Colgate-Palmolive released financial results that left me with mixed reactions. Demand for its products in Latin America is growing rapidly, but the strengthening of the US dollar has not allowed Colgate-Palmolive to fully reflect this in its EPS. In this article, you, Seeking Alpha readers, will learn why, according to my "ALLKA 4D Rating" model, Colgate-Palmolive is a stock with an attractive risk/reward ratio. Read the full article on Seeking AlphaSeeking Alpha • Mar 14
Is Colgate-Palmolive Quietly Building The Next Pet Food Empire?
Summary Colgate-Palmolive's premiumization strategy and pet nutrition expansion offer significant growth potential, with a price target of $115 per share, suggesting a 26% upside. Despite high valuation metrics, CL's superior profitability, high margins, and exceptional cash flow justify its premium valuation and long-term investment appeal. The company's strong pricing power, particularly in premium oral care and pet food, positions it well against inflation and competitive pressures. Risks include potential valuation compression and competition in pet nutrition, but CL's consistent cash flow and brand strength mitigate these concerns. Read the full article on Seeking AlphaSeeking Alpha • Feb 25
Colgate-Palmolive: Don't Get Your Hopes Up (Yet)
Summary After a strong first half of 2024, Colgate-Palmolive's stock continues to be an underperformer in the consumer staples sector. The stock is trading at a discount to the level implied by current margins, but there is a good reason for that. Margins are likely to come under pressure in 2025 and from a dividend point of view, CL also appears unattractive at the moment. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Colgate-Palmolive Stock: Post-Earnings Drop Isn't A Buy-The-Dip Moment
Summary Toothpaste and manual toothbrushes market leader Colgate-Palmolive Company released its fourth quarter and full-year 2024 results today. Judging by the share price reaction, and considering CL stock is down more than 20% from its all-time high, this clearly looks like a “buy the dip” moment. However, I'll explain why I don't think it's a good idea to buy CL shares, either for dividend or total return investors, and despite the company's undoubtedly solid 2024 performance. Read the full article on Seeking AlphaSeeking Alpha • Dec 17
Colgate-Palmolive: Digital Advertising Is The Base From Which To Start Again
Summary Colgate-Palmolive's (CL) revenue growth has been minimal over the past decade, with a CAGR of only 1.53%, not even keeping pace with inflation. Despite a 61-year streak of increasing dividends, CL's EPS growth has been stagnant, leading to a higher payout ratio. Increased advertising expenditures, particularly in digital, have shown higher ROI than traditional channels. CL's future growth may hinge on digital advertising and expanding into Personal and Home Care markets, but the current valuation is too high for a buy rating. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Colgate-Palmolive: Approaching Buy Territory With Some Important Catalysts
Summary As expected, Colgate-Palmolive's stock has retreated from its recent highs over the past few months. Upside potential for 2025 remains limited as gross margin tailwinds are fading. Nonetheless, there are some key areas that investors should keep a close eye on over the course of next year. Read the full article on Seeking AlphaSeeking Alpha • Oct 25
Colgate-Palmolive Q3: Great Company, But Not Enough To Warrant A Position Now
Summary Colgate-Palmolive Company's Q3 earnings showed mixed results, with revenue and EPS beating estimates but North America and Latin America sales declining, leading to a 3% stock drop. The company's improved gross margins and increased advertising spend are positive signs, but the market remains concerned about regional sales declines. The Pet Nutrition segment shows strong growth potential, driven by the pet humanization trend, and could be a key revenue catalyst. Given macroeconomic uncertainties and regional performance, I rate Colgate-Palmolive stock as a hold, awaiting further developments in NA, LatAm, and Pet Nutrition segments. Read the full article on Seeking AlphaSeeking Alpha • Oct 17
Colgate-Palmolive: Very Close To A Buy Following Recent Pullback
Summary Colgate-Palmolive is a high-quality business with consistent revenue growth, stable gross profit margins, and a strong return on invested capital, making it a solid dividend stock. The company has an impressive 61-year streak of consecutive dividend growth, maintaining a healthy payout ratio of around 60%, ensuring future dividend increases. The recent pace of dividend growth is below par but in line with inflation and top-line business growth. The recent pullback has brought the share price down very close to fair value. With earnings around the corner now may be a good time to consider jumping aboard. Colgate has beaten earnings estimates during the last 5 consecutive quarters, and recent analyst revisions indicate FQ3 may follow suit. Read the full article on Seeking AlphaSeeking Alpha • Sep 30
Colgate-Palmolive: Share Price Returns Should Moderate (Rating Downgrade)
Summary Since I turned bullish on the stock, Colgate-Palmolive delivered a 36% total return in less than 10 months. For a consumer staples company the size of CL, returns will most likely moderate from here for two main reasons. As the impact of pricing initiatives fades away, investors should keep a close eye on volumes over the coming year. Read the full article on Seeking AlphaSeeking Alpha • Aug 19
Colgate-Palmolive: Stability Pillar Reached Its Fair Value
Summary Colgate-Palmolive operates globally with a strong presence in over 200 countries, deriving two-thirds of revenue from non-US markets. The Company is a member of the Dividend Kings group, offering reliable dividend income, which grew consecutively for 60 years. Strong organic growth in primary segments (partially offset by FX fluctuations), with profitable operations and solid margins ensuring shareholder rewards. Upon stock price increases during the last couple of quarters, CL's multiple reached its fair level. Therefore, I remain a happy holder, but I've stopped adding. Read the full article on Seeking AlphaAktionärsrenditen
| CL | US Household Products | US Markt | |
|---|---|---|---|
| 7D | 0.7% | -3.0% | -0.9% |
| 1Y | -3.4% | -14.2% | 24.4% |
Rendite im Vergleich zur Industrie: CL übertraf die Branche US Household Products , die im vergangenen Jahr eine Rendite von -14.2 erzielte.
Rendite vs. Markt: CL hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 24.4 erzielte.
Preisvolatilität
| CL volatility | |
|---|---|
| CL Average Weekly Movement | 3.3% |
| Household Products Industry Average Movement | 3.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: CL hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CLDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1806 | 33,600 | Noel Wallace | www.colgatepalmolive.com |
Colgate-Palmolive Company produziert und verkauft zusammen mit ihren Tochtergesellschaften Konsumgüter in den Vereinigten Staaten und international. Das Unternehmen ist in zwei Segmenten tätig: Mund-, Körper- und Haushaltspflege und Tiernahrung. Das Segment Mund-, Körper- und Haushaltspflege bietet Zahnpasta, Zahnbürsten, Mundwasser, Handseifen in Stangen- und Flüssigform, Duschgels, Shampoos, Conditioner, Deodorants und Antitranspirantien, Hautpflegeprodukte, Geschirrspülmittel, Weichspüler, Haushaltsreiniger und andere verwandte Produkte an.
Colgate-Palmolive Company's Grundlagenzusammenfassung
| CL grundlegende Statistiken | |
|---|---|
| Marktanteil | US$71.09b |
| Gewinn(TTM) | US$2.09b |
| Umsatz(TTM) | US$20.80b |
33.8x
Kurs-Gewinn-Verhältnis 3.4x
Kurs-Umsatz-VerhältnisIst CL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$20.80b |
| Kosten der Einnahmen | US$8.31b |
| Bruttogewinn | US$12.49b |
| Sonstige Ausgaben | US$10.40b |
| Gewinn | US$2.09b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Jul 31, 2026
| Gewinn per Aktie (EPS) | 2.61 |
| Bruttomarge | 60.06% |
| Nettogewinnspanne | 10.04% |
| Schulden/Eigenkapital-Verhältnis | 1,640.5% |
Wie hat sich CL auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
2.4%
Aktuelle Dividendenrendite80%
AusschüttungsquoteZahlt CL eine zuverlässige Dividende?
Siehe CL Dividendenhistorie und Benchmarks| Colgate-Palmolive Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Apr 20 2026 |
| Datum der Dividendenzahlung | May 15 2026 |
| Tage bis Ex-Dividende | 27 days |
| Tage bis zum Datum der Dividendenzahlung | 2 days |
Zahlt CL eine zuverlässige Dividende?
Siehe CL Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/15 20:57 |
| Aktienkurs zum Tagesende | 2026/05/15 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Colgate-Palmolive Company wird von 43 Analysten beobachtet. 17 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Christopher Graja | Argus Research Company |
| Lauren Lieberman | Barclays |
| Lauren Lieberman | Barclays |